A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Oral Doses of ARN-6039 in Healthy Adult Subjects.
Phase of Trial: Phase I
Latest Information Update: 08 Aug 2017
At a glance
- Drugs ARN 6039 (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Arrien Pharmaceuticals
- 28 Jun 2017 According to an Arrien Pharmaceuticals media release, status changed from recruiting to completed.
- 09 Jun 2016 New trial record